Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma - a Randomized, Open Label, 3 Arm Multicenter Phase I Trial to Assess Safety, Tolerability and Immunogenicity of IDH1R132H-specific Peptide Vaccine in Combination with Checkpoint Inhibitor Avelumab

NCT03893903 is registered in ClinicalTrials.gov with German Cancer Research Center as lead sponsor.

NCT NCT03893903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03893903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma - a Randomized, Open Label, 3 Arm Multicenter Phase I Trial to Assess Safety, Tolerability and Immunogenicity of IDH1R132H-specific Peptide Vaccine in Combination with Checkpoint Inhibitor Avelumab
Lead sponsor
German Cancer Research Center
Phase
Phase 1
Overall status
Completed
Start date
October 19, 2018
Completion date
September 20, 2024
Enrollment
69 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

malignant glioma